Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from NetraMark Holdings ( (TSE:AIAI) ).
NetraMark Holdings has successfully completed a Critical Path Innovation Meeting with the U.S. FDA, discussing its NetraAI platform’s potential in clinical trial design. This milestone marks a significant step in regulatory engagement, offering potential pathways for further dialogue and enhancing trial efficiency and success for sponsors.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leading artificial intelligence company specializing in transforming clinical trials through AI-powered precision analytics within the pharmaceutical industry.
YTD Price Performance: 17.65%
Average Trading Volume: 49,185
Technical Sentiment Signal: Hold
Current Market Cap: C$103M
See more data about AIAI stock on TipRanks’ Stock Analysis page.